Olaparib after surgery for recurrent ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult woman (18+) and sign consent before any trial procedures
- Have recurrent or worsening high-grade ovarian/fallopian tube/primary peritoneal cancer after first-line PARPi maintenance
- Have had only one prior platinum chemotherapy treatment, and it did not include bevacizumab
- Have already had PARPi treatment for at least 6 months (and if it was olaparib, it must have been tolerated without major ongoing side effects or permanent dose reduction)
- Have had secondary cytoreductive surgery, with no visible leftover tumor (or resection of the main progressive spot) and start trial treatment 3–8 weeks after surgery
- Have a documented BRCA1/2 test result (or agree to provide blood/tissue for BRCA testing before enrollment) and be able to swallow pills
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a second course of niraparib (a PARP inhibitor) after surgery for ovarian cancer that has come back in just a few spots. It aims to see if restarting niraparib can help keep the cancer from coming back again.
This trial tests whether doing additional (“secondary”) tumor-removal surgery can help people with ovarian, fallopian tube, or primary peritoneal cancer that has returned after PARP inhibitor maintenance. It focuses on people whose cancer can likely be fully removed and who are considered good candidates for surgery and follow-up treatment.
This trial compares two drug combinations (fluzoparib plus bevacizumab versus olaparib plus bevacizumab) given after initial chemotherapy to keep advanced ovarian cancer from coming back. Participants must have a specific genetic marker (HRD-positive) and have responded well to their first treatment.
This trial tests if adding a drug called a PARP inhibitor (which helps block cancer cells from repairing themselves) to standard chemotherapy and heated chemotherapy during surgery (HIPEC) can work better together for ovarian cancer that has already been treated with initial chemo. It is for people with a specific type of advanced ovarian cancer who are planning surgery after chemo.
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
This trial tests whether a maintenance treatment (fluzoparil and apatinib) can help keep ovarian cancer from coming back after successful platinum-based chemotherapy. It is for women whose cancer either came back within 6 months of their last treatment (platinum-resistant) or more than 6 months later (platinum-sensitive) and who have responded to further chemo.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.